capecitabine mylan 150 mg, filmomhulde tabletten
mylan b.v. - capecitabine - filmomhulde tablet - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), - capecitabine
capecitabine mylan 500 mg, filmomhulde tabletten
mylan b.v. - capecitabine - filmomhulde tablet - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), - capecitabine
capecitabine actavis 150 mg filmomh. tabl.
actavis group ptc ehf - capecitabine 150 mg - filmomhulde tablet - 150 mg - capecitabine 150 mg - capecitabine
capecitabine actavis 500 mg filmomh. tabl.
actavis group ptc ehf - capecitabine 500 mg - filmomhulde tablet - 500 mg - capecitabine 500 mg - capecitabine
capecitabine fair-med 150 mg filmomh. tabl.
fair-med healthcare gmbh - capecitabine 150 mg - filmomhulde tablet - 150 mg - capecitabine 150 mg - capecitabine
capecitabine fair-med 500 mg filmomh. tabl.
fair-med healthcare gmbh - capecitabine 500 mg - filmomhulde tablet - 500 mg - capecitabine 500 mg - capecitabine
capecitabine glenmark 150 mg filmomhulde tabletten
capecitabine 150 mg/stuk - filmomhulde tablet
capecitabine glenmark 500 mg filmomhulde tabletten
capecitabine 500 mg/stuk - filmomhulde tablet
elvorine 50 mg/5 ml inj. opl. i.v./i.m. flac.
pfizer sa-nv - calciumlevofolinaat - eq. levofolinezuur 10 mg/ml - oplossing voor injectie - 10 mg/ml - calciumlevofolinaat - calcium levofolinate
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - maagneoplasma - antineoplastische middelen - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.